Kodiak Sciences Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapeutics to treat ophthalmic diseases. The Company’s Antibody Biopolymer Conjugate (ABC) platform focuses on merging the fields of antibody-based and chemistry-based therapies. The Company in addition to its lead product candidate, KSI-301, is a molecule for age-related macular degeneration and diabetic retinopathy. The Company has leveraged its ABC platform to build a pipeline of product candidates in various stages of development including KSI-501, a dual inhibitor ABC for the treatment of neovascular retinal diseases, such as wet AMD and diabetic retinopathy.
Q3 2019(9/30/19): Cash 60.60M. Loss 23.61M
EPS and Sales:
|Date||EPS||% last year||% last quarter|
Total institutions: 76，no change
Shares hold: 25049k shares. no change
shares% hold: 67.59%，no change